ANC’s Clinical Trial Research
Here at ANC, we are thrilled to announce our participation in global clinical trials focused on
developing new treatments for people with kidney disease. We are partnering with Davita
Clinical Research to bring opportunities for our patients to have access to developing, cutting-
edge treatments early on and we are excited to share this opportunity with you and anyone
affected by kidney disease.
Historically, participation in impactful research was often limited to very large practices and well-
funded institutions far away from the Twin Cities. Now, as interest grows and more resources
become available for studies in kidney disease, ANC and our partners at Intermed Consultants
bring opportunities to our patients close to home.
Key Studies at ANC and Intermed Consultants
(1) Hyperparathyroidism in Dialysis Patients
One study participating in focuses on hyperparathyroidism in dialysis patients.
Hyperparathyroidism is a complication in dialysis patients where over-activity of the parathyroid
glands leads to bone disease. This trial takes place in our dialysis units and aims to improve
calcium-phosphate balance in the body and prevent common dialysis complications.
(2) Therapies for Specific Glomerular Diseases
We are recruiting for several studies of glomerular diseases which cause inflammation in kidney
filters and can lead to kidney failure. In the past, we did not have good treatments for some of
these diseases but now there’s been a lot of research, and promising new treatments have
been developed. If you or someone you know has IgA Nephropathy, Focal Sclerosis, or
Membranous Nephropathy, you may be eligible for a new drug trial.
(3) Genetic Chronic Kidney Disease (CKD)
We are recruiting for a new study for patients with a genetic abnormality that raises the risk of
severe kidney disease. Though 10% of the U.S. population is African American, they make up
nearly 30% of dialysis patients. Abnormalities in the APOL1 gene are thought to be common in
these individuals and explain much of the high incidence of severe kidney disease in African
Americans. There is an open study testing a new drug in patients with this genetic marker. If
you are interested, screening for this gene is offered at no cost. For individuals with this genetic
marker, there is a new treatment being tested to prevent kidney damage in patients with
abnormal APOL1 variants.
Getting Involved
If you or someone you know is interested in more information on time commitment, trial
protocols, and compensation or participating in a clinical trial, call us.
